NASDAQ:INFI - Infinity Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.96 -0.03 (-1.51 %)
(As of 05/22/2018 06:06 AM ET)
Previous Close$1.99
Today's Range$1.92 - $2.05
52-Week Range$0.93 - $3.75
Volume380,597 shs
Average Volume404,675 shs
Market Capitalization$111.58 million
P/E Ratio-2.36
Dividend YieldN/A
Beta2.5

About Infinity Pharmaceuticals (NASDAQ:INFI)

Infinity Pharmaceuticals logoInfinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib, as well as duvelisib program, including DUO study that is in randomized and monotherapy Phase III clinical study for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate; and AbbVie Inc. to develop and commercialize products containing duvelisib in oncology indications. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

Receive INFI News and Ratings via Email

Sign-up to receive the latest news and ratings for INFI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:INFI
CUSIP45665G30
Phone617-453-1000

Debt

Debt-to-Equity RatioN/A
Current Ratio10.81
Quick Ratio10.81

Price-To-Earnings

Trailing P/E Ratio-2.36
Forward P/E Ratio-2.65
P/E GrowthN/A

Sales & Book Value

Annual Sales$6 million
Price / Sales18.32
Cash FlowN/A
Price / CashN/A
Book Value$0.94 per share
Price / Book2.09

Profitability

EPS (Most Recent Fiscal Year)($0.83)
Net Income$-41,830,000.00
Net MarginsN/A
Return on Equity-79.47%
Return on Assets-61.73%

Miscellaneous

Employees22
Outstanding Shares56,070,000

Infinity Pharmaceuticals (NASDAQ:INFI) Frequently Asked Questions

What is Infinity Pharmaceuticals' stock symbol?

Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."

How were Infinity Pharmaceuticals' earnings last quarter?

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) posted its quarterly earnings results on Tuesday, May, 8th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.18) by $0.00. View Infinity Pharmaceuticals' Earnings History.

Who are some of Infinity Pharmaceuticals' key competitors?

Who are Infinity Pharmaceuticals' key executives?

Infinity Pharmaceuticals' management team includes the folowing people:
  • Ms. Adelene Q. Perkins, Chairman & CEO (Age 58)
  • Dr. Lawrence E. Bloch M.D., J.D., Pres, Principal Accounting Officer & Treasurer (Age 52)
  • Mr. Seth A. Tasker J.D., VP, Gen. Counsel & Sec. (Age 39)
  • Ms. Melissa Hackel, VP of Fin.
  • Dr. Jeffery L. Kutok M.D., Ph.D., Chief Scientific Officer & Sr. VP (Age 51)

Has Infinity Pharmaceuticals been receiving favorable news coverage?

Press coverage about INFI stock has trended somewhat positive on Tuesday, according to Accern Sentiment. Accern rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Infinity Pharmaceuticals earned a coverage optimism score of 0.20 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 46.55 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are Infinity Pharmaceuticals' major shareholders?

Infinity Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include BIOTECHNOLOGY VALUE FUND L P (21.70%), Dimensional Fund Advisors LP (1.31%), Wasatch Advisors Inc. (0.64%), Millennium Management LLC (0.58%), GSA Capital Partners LLP (0.54%) and Wells Fargo & Company MN (0.35%). Company insiders that own Infinity Pharmaceuticals stock include Adelene Q Perkins, Lawrence E Bloch, Michael C Venuti, Sujay Kango and Value Fund L P Biotechnology. View Institutional Ownership Trends for Infinity Pharmaceuticals.

Which institutional investors are selling Infinity Pharmaceuticals stock?

INFI stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and Clear Harbor Asset Management LLC. View Insider Buying and Selling for Infinity Pharmaceuticals.

Which institutional investors are buying Infinity Pharmaceuticals stock?

INFI stock was acquired by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Dimensional Fund Advisors LP, GSA Capital Partners LLP and Wells Fargo & Company MN. Company insiders that have bought Infinity Pharmaceuticals stock in the last two years include Lawrence E Bloch and Value Fund L P Biotechnology. View Insider Buying and Selling for Infinity Pharmaceuticals.

How do I buy shares of Infinity Pharmaceuticals?

Shares of INFI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Infinity Pharmaceuticals' stock price today?

One share of INFI stock can currently be purchased for approximately $1.96.

How big of a company is Infinity Pharmaceuticals?

Infinity Pharmaceuticals has a market capitalization of $111.58 million and generates $6 million in revenue each year. The biotechnology company earns $-41,830,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. Infinity Pharmaceuticals employs 22 workers across the globe.

How can I contact Infinity Pharmaceuticals?

Infinity Pharmaceuticals' mailing address is 784 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-453-1000 or via email at [email protected]


MarketBeat Community Rating for Infinity Pharmaceuticals (INFI)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  241 (Vote Outperform)
Underperform Votes:  264 (Vote Underperform)
Total Votes:  505
MarketBeat's community ratings are surveys of what our community members think about Infinity Pharmaceuticals and other stocks. Vote "Outperform" if you believe INFI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INFI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Infinity Pharmaceuticals (NASDAQ:INFI) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Infinity Pharmaceuticals in the last 12 months. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Infinity Pharmaceuticals (NASDAQ:INFI) Consensus Price Target History

Price Target History for Infinity Pharmaceuticals (NASDAQ:INFI)

Infinity Pharmaceuticals (NASDAQ:INFI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/12/2017Wells FargoUpgradeMarket Perform ➝ OutperformN/AView Rating Details
11/10/2016JPMorgan ChaseReiterated RatingHoldN/AView Rating Details
8/11/2016Morgan StanleyReiterated RatingHold$1.00N/AView Rating Details
8/10/2016FBR & CoReiterated RatingHoldN/AView Rating Details
8/9/2016WedbushReiterated RatingNeutral$1.25 ➝ $1.00N/AView Rating Details
6/15/2016Jefferies GroupDowngradeBuy ➝ HoldN/AView Rating Details
6/15/2016William BlairDowngradeOutperform ➝ Market Perform$20.00 ➝ $2.00N/AView Rating Details
6/14/2016Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$12.00 ➝ $2.00N/AView Rating Details
6/14/2016JMP SecuritiesDowngradeOutperform ➝ Market PerformN/AView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Infinity Pharmaceuticals (NASDAQ:INFI) Earnings History and Estimates Chart

Earnings by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)

Infinity Pharmaceuticals (NASDAQ:INFI) Earnings Estimates

2018 EPS Consensus Estimate: ($0.91)
2019 EPS Consensus Estimate: ($0.60)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.30)($0.30)($0.30)
Q2 20181($0.21)($0.21)($0.21)
Q3 20181($0.21)($0.21)($0.21)
Q4 20181($0.19)($0.19)($0.19)
Q1 20191$0.18$0.18$0.18
Q2 20191($0.25)($0.25)($0.25)
Q3 20191($0.26)($0.26)($0.26)
Q4 20191($0.27)($0.27)($0.27)

Infinity Pharmaceuticals (NASDAQ INFI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018Q1 2018($0.1820)($0.18)ViewN/AView Earnings Details
3/15/2018Q4 2017($0.25)($0.14)ViewListenView Earnings Details
11/7/2017Q3 2017($0.20)($0.14)$14.70 million$6.00 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.22)($0.34)ViewListenView Earnings Details
5/9/2017Q1 2017($0.22)($0.21)$19.60 million$0.01 millionViewListenView Earnings Details
3/14/2017Q4 2016($0.57)($0.46)$2.33 millionViewN/AView Earnings Details
11/9/2016Q316($0.84)($0.39)$6.23 millionViewListenView Earnings Details
8/9/2016Q216($0.89)$1.05$13.91 million$9.47 millionViewListenView Earnings Details
5/4/2016Q116($0.82)($0.82)$8.80 million$9.26 millionViewListenView Earnings Details
2/23/2016Q415($0.72)($0.80)$18.26 million$9.10 millionViewListenView Earnings Details
11/5/2015Q315($0.76)$0.84$24.85 million$90.70 millionViewN/AView Earnings Details
8/6/2015Q215($1.00)($0.78)$5.83 million$4.90 millionViewN/AView Earnings Details
5/6/2015Q115($1.69)($1.91)$5.79 million$4.40 millionViewListenView Earnings Details
2/24/2015Q414($0.99)($0.83)$5.61 million$4.36 millionViewListenView Earnings Details
11/6/2014Q314($0.87)$2.03$141.40 million$160.60 millionViewListenView Earnings Details
8/5/2014Q114($0.84)($0.78)ViewN/AView Earnings Details
5/6/2014Q1($0.80)($0.87)ViewListenView Earnings Details
2/25/2014Q413($0.87)($0.68)ViewListenView Earnings Details
11/7/2013($0.75)($0.71)ViewN/AView Earnings Details
8/8/2013Q2 2013($0.62)($0.68)ViewListenView Earnings Details
5/7/2013Q1 2013($0.67)($0.57)ViewN/AView Earnings Details
3/5/2013Q4 2012($0.89)($1.15)ViewN/AView Earnings Details
11/6/2012Q312($0.57)$0.52$13.90 millionViewN/AView Earnings Details
8/7/2012Q2 2012($0.38)($0.54)ViewN/AView Earnings Details
5/8/2012Q1 2012($0.37)($0.40)ViewN/AView Earnings Details
3/13/2012Q4 2011($0.42)($0.53)ViewN/AView Earnings Details
11/8/2011Q3 2011($0.40)($0.45)ViewN/AView Earnings Details
8/9/2011Q2 2011($0.36)($0.44)ViewN/AView Earnings Details
5/10/2011Q1 2011($0.36)($0.09)ViewN/AView Earnings Details
3/15/2011Q4 2010($0.39)($0.56)ViewN/AView Earnings Details
11/9/2010Q3 2010($0.76)($0.81)ViewN/AView Earnings Details
8/4/2010Q2 2010($0.32)($0.24)ViewN/AView Earnings Details
5/6/2010Q1 2010($0.34)($0.32)ViewN/AView Earnings Details
2/10/2010Q4 2009($0.42)($0.30)ViewN/AView Earnings Details
11/9/2009Q3 2009($0.44)($0.36)ViewN/AView Earnings Details
8/5/2009Q2 2009($0.52)($0.50)ViewN/AView Earnings Details
5/4/2009Q1 2009($0.08)($0.15)ViewN/AView Earnings Details
2/9/2009Q4 2008$1.01$2.11ViewN/AView Earnings Details
10/29/2008Q3 2008($0.57)($0.63)ViewN/AView Earnings Details
8/4/2008Q2 2008($0.41)($0.57)ViewN/AView Earnings Details
5/5/2008Q1 2008($0.37)$0.02ViewN/AView Earnings Details
2/13/2008Q4 2007($0.27)($0.40)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Infinity Pharmaceuticals (NASDAQ:INFI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Infinity Pharmaceuticals (NASDAQ INFI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 11.45%
Institutional Ownership Percentage: 50.55%
Insider Trading History for Infinity Pharmaceuticals (NASDAQ:INFI)
Institutional Ownership by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)

Infinity Pharmaceuticals (NASDAQ INFI) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/10/2018Value Fund L P BiotechnologyMajor ShareholderBuy1,510,000$1.97$2,974,700.00View SEC Filing  
3/5/2018Adelene Q PerkinsCEOSell5,000$2.78$13,900.00607,252View SEC Filing  
12/6/2017Lawrence E BlochPresidentBuy500,000$1.81$905,000.00580,944View SEC Filing  
10/4/2017Value Fund L P BiotechnologyInsiderBuy1,600,046$1.26$2,016,057.96View SEC Filing  
3/17/2017Michael C VenutiDirectorSell6,250$3.48$21,750.0050,000View SEC Filing  
1/3/2017Value Fund L P BiotechnologyMajor ShareholderBuy4,379$1.34$5,867.86View SEC Filing  
12/30/2016Value Fund L P BiotechnologyMajor ShareholderBuy742,401$1.34$994,817.34View SEC Filing  
12/20/2016Value Fund L P BiotechnologyMajor ShareholderBuy654,921$1.31$857,946.51View SEC Filing  
12/13/2016Sujay KangoInsiderSell75,000$1.28$96,000.0050,590View SEC Filing  
12/12/2016Sujay KangoInsiderSell25,009$1.30$32,511.7050,590View SEC Filing  
12/2/2016Value Fund L P BiotechnologyMajor ShareholderBuy201,394$1.19$239,658.86View SEC Filing  
6/25/2015Adelene Q PerkinsCEOSell5,000$10.93$54,650.00View SEC Filing  
6/15/2015Vito J PalombellaInsiderSell4,737$10.97$51,964.89View SEC Filing  
5/27/2015Adelene Q PerkinsCEOSell10,000$12.81$128,100.00View SEC Filing  
5/14/2015Adelene Q PerkinsCEOSell10,000$12.18$121,800.00View SEC Filing  
3/16/2015Adelene Q PerkinsCEOSell20,000$16.00$320,000.00View SEC Filing  
1/29/2015Adelene Q PerkinsCEOSell20,000$14.83$296,600.00View SEC Filing  
12/15/2014Vito J PalombellaInsiderSell4,737$16.32$77,307.84View SEC Filing  
11/26/2014Vito J PalombellaInsiderSell4,736$15.00$71,040.00View SEC Filing  
9/30/2014Anthony B EvninDirectorSell112,451$13.56$1,524,835.56View SEC Filing  
9/3/2014Vito J PalombellaInsiderSell9,472$15.39$145,774.08View SEC Filing  
11/27/2013Anthony B EvninDirectorSell163,864$14.82$2,428,464.48View SEC Filing  
9/13/2013Adelene PerkinsCEOSell45,000$20.72$932,400.00447,535View SEC Filing  
6/20/2013Vito J PalombellaInsiderSell23,150$18.53$428,969.50View SEC Filing  
11/26/2012Christopher M LindblomInsiderSell13,885$25.73$357,261.05View SEC Filing  
9/7/2012Co BeaconMajor ShareholderBuy5,416,565$14.50$78,540,192.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Infinity Pharmaceuticals (NASDAQ INFI) News Headlines

Source:
DateHeadline
Zacks Investment Research Lowers Infinity Pharmaceuticals (INFI) to HoldZacks Investment Research Lowers Infinity Pharmaceuticals (INFI) to Hold
www.americanbankingnews.com - May 16 at 1:35 PM
Pancreatic Cancer Market is Determined to Cross US$ 13 Billion By 2023Pancreatic Cancer Market is Determined to Cross US$ 13 Billion By 2023
www.marketwatch.com - May 14 at 5:20 PM
 Brokerages Anticipate Infinity Pharmaceuticals, Inc. (INFI) to Announce -$0.19 EPS Brokerages Anticipate Infinity Pharmaceuticals, Inc. (INFI) to Announce -$0.19 EPS
www.americanbankingnews.com - May 11 at 11:24 AM
William Blair Weighs in on Infinity Pharmaceuticals, Inc.s Q2 2018 Earnings (INFI)William Blair Weighs in on Infinity Pharmaceuticals, Inc.'s Q2 2018 Earnings (INFI)
www.americanbankingnews.com - May 11 at 9:35 AM
Edited Transcript of INFI earnings conference call or presentation 8-May-18 8:30pm GMTEdited Transcript of INFI earnings conference call or presentation 8-May-18 8:30pm GMT
finance.yahoo.com - May 11 at 8:28 AM
Analysts Offer Predictions for Infinity Pharmaceuticals, Inc.s Q1 2019 Earnings (INFI)Analysts Offer Predictions for Infinity Pharmaceuticals, Inc.'s Q1 2019 Earnings (INFI)
www.americanbankingnews.com - May 10 at 8:42 AM
Infinity Pharmaceuticals (INFI) Posts  Earnings Results, Hits EstimatesInfinity Pharmaceuticals (INFI) Posts Earnings Results, Hits Estimates
www.americanbankingnews.com - May 9 at 1:31 PM
Infinity Pharmaceuticals (INFI) CEO Adelene Perkins on Q1 2018 Results - Earnings Call TranscriptInfinity Pharmaceuticals' (INFI) CEO Adelene Perkins on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 8:19 AM
Infinity: 1Q Earnings SnapshotInfinity: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 8:19 AM
Infinity Pharmaceuticals Provides Company Update and First Quarter 2018 Financial ResultsInfinity Pharmaceuticals Provides Company Update and First Quarter 2018 Financial Results
www.bizjournals.com - May 8 at 5:39 PM
BRIEF-Infinity Pharmaceuticals Q1 Loss Per Share $0.18BRIEF-Infinity Pharmaceuticals Q1 Loss Per Share $0.18
www.reuters.com - May 8 at 5:39 PM
Infinity Announces The Date Of Its First Quarter 2018 Financial Results Conference Call And WebcastInfinity Announces The Date Of Its First Quarter 2018 Financial Results Conference Call And Webcast
finance.yahoo.com - May 1 at 5:18 PM
BRIEF-Infinity Pharmaceuticals Files Prospectus Relates To Resale Of Up To 1.1 Mln Shares Of Cos Common Stock - SEC FilingBRIEF-Infinity Pharmaceuticals Files Prospectus Relates To Resale Of Up To 1.1 Mln Shares Of Co's Common Stock - SEC Filing
www.reuters.com - May 1 at 8:26 AM
Gamida Cell Strengthens Leadership Team with Appointments of Josh Hamermesh as Chief Business Officer and Paul ...Gamida Cell Strengthens Leadership Team with Appointments of Josh Hamermesh as Chief Business Officer and Paul ...
www.businesswire.com - April 26 at 8:17 AM
Form DEF 14A INFINITY PHARMACEUTICALS For: Jun 12Form DEF 14A INFINITY PHARMACEUTICALS For: Jun 12
www.streetinsider.com - April 26 at 8:17 AM
MaxCyte Appoints Dr. Claudio Dansky Ullmann as Chief Medical OfficerMaxCyte Appoints Dr. Claudio Dansky Ullmann as Chief Medical Officer
www.prnewswire.com - April 26 at 8:17 AM
 Brokerages Expect Infinity Pharmaceuticals Inc. (INFI) to Announce -$0.18 Earnings Per Share Brokerages Expect Infinity Pharmaceuticals Inc. (INFI) to Announce -$0.18 Earnings Per Share
www.americanbankingnews.com - April 23 at 11:10 PM
Why Is Infinity Pharmaceuticals (INFI) Down 18.3% Since its Last Earnings Report?Why Is Infinity Pharmaceuticals (INFI) Down 18.3% Since its Last Earnings Report?
finance.yahoo.com - April 16 at 8:16 AM
BRIEF-BVF Partners Reports 21.7 Pct Stake In Infinity Pharmaceuticals As Of April 10BRIEF-BVF Partners Reports 21.7 Pct Stake In Infinity Pharmaceuticals As Of April 10
www.reuters.com - April 13 at 8:19 AM
Why Infinity Pharmaceuticals (INFI) Could Shock the Market SoonWhy Infinity Pharmaceuticals (INFI) Could Shock the Market Soon
finance.yahoo.com - April 12 at 5:38 PM
Insider Buying: Infinity Pharmaceuticals Inc. (INFI) Major Shareholder Acquires 1,510,000 Shares of StockInsider Buying: Infinity Pharmaceuticals Inc. (INFI) Major Shareholder Acquires 1,510,000 Shares of Stock
www.americanbankingnews.com - April 11 at 7:09 PM
-$0.18 Earnings Per Share Expected for Infinity Pharmaceuticals Inc. (INFI) This Quarter-$0.18 Earnings Per Share Expected for Infinity Pharmaceuticals Inc. (INFI) This Quarter
www.americanbankingnews.com - April 7 at 1:13 AM
Zacks Investment Research Upgrades Infinity Pharmaceuticals (INFI) to "Hold"Zacks Investment Research Upgrades Infinity Pharmaceuticals (INFI) to "Hold"
www.americanbankingnews.com - April 6 at 8:45 PM
Are Options Traders Betting on a Big Move in Infinity Pharmaceuticals (INFI) Stock?Are Options Traders Betting on a Big Move in Infinity Pharmaceuticals (INFI) Stock?
www.zacks.com - March 28 at 8:28 AM
Infinity Pharmaceuticals (INFI) Presents At BioCenturys 25th Annual Future Leaders In The Biotech Industry Conference - SlideshowInfinity Pharmaceuticals (INFI) Presents At BioCentury's 25th Annual Future Leaders In The Biotech Industry Conference - Slideshow
seekingalpha.com - March 27 at 5:14 PM
Infinity to Present at Two Upcoming ConferencesInfinity to Present at Two Upcoming Conferences
finance.yahoo.com - March 26 at 5:18 PM
Can The Uptrend Continue for Infinity Pharmaceuticals (INFI)?Can The Uptrend Continue for Infinity Pharmaceuticals (INFI)?
finance.yahoo.com - March 22 at 8:26 AM
Infinity To Present At BioCenturys 25th Annual Future Leaders In The Biotech Industry ConferenceInfinity To Present At BioCentury's 25th Annual Future Leaders In The Biotech Industry Conference
finance.yahoo.com - March 21 at 5:37 PM
 Brokerages Anticipate Infinity Pharmaceuticals Inc. (INFI) Will Announce Earnings of -$0.18 Per Share Brokerages Anticipate Infinity Pharmaceuticals Inc. (INFI) Will Announce Earnings of -$0.18 Per Share
www.americanbankingnews.com - March 21 at 1:26 AM
William Blair Comments on Infinity Pharmaceuticals Inc.s Q1 2019 Earnings (INFI)William Blair Comments on Infinity Pharmaceuticals Inc.'s Q1 2019 Earnings (INFI)
www.americanbankingnews.com - March 19 at 5:16 AM
Infinity (INFI) Reports Narrower-than-Expected Loss in Q4 - NasdaqInfinity (INFI) Reports Narrower-than-Expected Loss in Q4 - Nasdaq
www.nasdaq.com - March 17 at 8:26 AM
Edited Transcript of INFI earnings conference call or presentation 15-Mar-18 8:30pm GMTEdited Transcript of INFI earnings conference call or presentation 15-Mar-18 8:30pm GMT
finance.yahoo.com - March 16 at 6:29 PM
Infinity Pharmaceuticals (INFI) Posts Quarterly  Earnings Results, Beats Estimates By $0.11 EPSInfinity Pharmaceuticals (INFI) Posts Quarterly Earnings Results, Beats Estimates By $0.11 EPS
www.americanbankingnews.com - March 16 at 9:44 AM
Infinity Pharmaceuticals Provides Company Update and Reports ... - PR Newswire (press release)Infinity Pharmaceuticals Provides Company Update and Reports ... - PR Newswire (press release)
www.prnewswire.com - March 16 at 8:20 AM
Infinity Pharmaceuticals (INFI) CEO Adelene Perkins on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaInfinity Pharmaceuticals' (INFI) CEO Adelene Perkins on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 16 at 8:20 AM
Infinity Pharmaceuticals Provides Company Update and Reports Fourth Quarter and Full Year 2017 Financial ResultsInfinity Pharmaceuticals Provides Company Update and Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 15 at 6:12 PM
Infinity Pharmaceuticals, Inc. to Host Earnings CallInfinity Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - March 15 at 6:12 PM
Infinity Pharmaceuticals Announces Additions to Board of Directors ... - PR Newswire (press release)Infinity Pharmaceuticals Announces Additions to Board of Directors ... - PR Newswire (press release)
www.prnewswire.com - March 9 at 8:20 AM
Infinity Announces the Date of Its Fourth Quarter and Full Year 2017 Financial Results Conference Call and WebcastInfinity Announces the Date of Its Fourth Quarter and Full Year 2017 Financial Results Conference Call and Webcast
finance.yahoo.com - March 8 at 6:43 PM
Infinity Pharmaceuticals Announces Additions to Board of Directors and Clinical Leadership Team and Establishes Scientific Advisory BoardInfinity Pharmaceuticals Announces Additions to Board of Directors and Clinical Leadership Team and Establishes Scientific Advisory Board
finance.yahoo.com - March 8 at 6:43 PM
Infinity Pharmaceuticals Inc. (INFI) CEO Sells $13,900.00 in StockInfinity Pharmaceuticals Inc. (INFI) CEO Sells $13,900.00 in Stock
www.americanbankingnews.com - March 7 at 7:46 PM
Head-To-Head Survey: Immunomedics (IMMU) vs. Infinity Pharmaceuticals (INFI)Head-To-Head Survey: Immunomedics (IMMU) vs. Infinity Pharmaceuticals (INFI)
www.americanbankingnews.com - March 5 at 11:36 AM
Infinity Pharmaceuticals (INFI) to Release Quarterly Earnings on MondayInfinity Pharmaceuticals (INFI) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - March 5 at 2:16 AM
-$0.25 EPS Expected for Infinity Pharmaceuticals Inc. (INFI) This Quarter-$0.25 EPS Expected for Infinity Pharmaceuticals Inc. (INFI) This Quarter
www.americanbankingnews.com - March 3 at 9:10 PM
Notice of Annual General Meeting Copenhagen Stock Exchange:LUN - GlobeNewswire (press release)Notice of Annual General Meeting Copenhagen Stock Exchange:LUN - GlobeNewswire (press release)
globenewswire.com - February 19 at 8:16 AM
Infinity Pharmaceuticals Inc. (INFI) Expected to Post Earnings of -$0.25 Per ShareInfinity Pharmaceuticals Inc. (INFI) Expected to Post Earnings of -$0.25 Per Share
www.americanbankingnews.com - February 15 at 3:16 AM
Mid-Morning Market Update: Markets Mostly Lower; Groupon Profit Misses ViewsMid-Morning Market Update: Markets Mostly Lower; Groupon Profit Misses Views
www.nasdaq.com - February 14 at 4:05 PM
Infinity Pharmaceuticals (INFI) Presents At BIO CEO & Investor Conference - SlideshowInfinity Pharmaceuticals (INFI) Presents At BIO CEO & Investor Conference - Slideshow
seekingalpha.com - February 13 at 3:44 PM
Infinity To Present At BIO CEO & Investor ConferenceInfinity To Present At BIO CEO & Investor Conference
finance.yahoo.com - February 5 at 9:34 AM
-$0.25 Earnings Per Share Expected for Infinity Pharmaceuticals Inc. (INFI) This Quarter-$0.25 Earnings Per Share Expected for Infinity Pharmaceuticals Inc. (INFI) This Quarter
www.americanbankingnews.com - January 29 at 5:12 AM

SEC Filings

Infinity Pharmaceuticals (NASDAQ:INFI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Infinity Pharmaceuticals (NASDAQ:INFI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Infinity Pharmaceuticals (NASDAQ INFI) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.